U.S. Trials
Title | # of Patients | Sites | Objective | Status |
---|---|---|---|---|
ANGEL Phase I Trial | 5 Patients | Hospital Angeles | Phase I study to assess safety and feasibility of AdipoCell™ | Enrollment Complete |
MARVEL (Phase II/III Clinical Trial) | MARVEL Part 1: 20 Patients (completed) MARVEL Part 2: 133 Patients | Up to 35 sites in the United States | Designed to be a double blind, randomized, placebo controlled multi-center trial to evaluate the safety and efficacy of MyoCell® delivered via MyoStar® | MyoCell® implantation procedure completed on first patient in October 2007. MARVEL part 1 data on the first 20 patients analyzed and presented at the Heart Failure Society of America (HFSA) Meeting in 2009. Data displayed overall positive clinical result |
MYOHEART (Phase I Clinical Trial) | 20 | Five sites in the United States | Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart. | Trial commenced in 2003; treatment of all 20 patients completed in October 2006; final twelve-month data presented in January 2008. |
REGEN (Phase I Clinical Trial) | 15 | 3 Sites in US | Designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein | Approval received in July 2009 from the FDA to move forward with the trail. |
European Trials
Title | # of Patients | Sites | Objective | Status |
---|---|---|---|---|
2002 Trial | 3 | One site in the Netherlands | Trial commenced in 2002. Discontinued upon Transvascular's acquisition by Medtronic. | |
Netherlands Phase I Clinical Trial | 5 | One site in the Netherlands | Pilot study to assess safety and feasibility of MyoCell®. | Trail commenced in 2001; six-month follow-up completed in October 2003. |
Phase I/II Clinical Trial | 15 | Three sites in the Netherlands, Germany and Italy. | Trial commenced in 2002; twelve-month follow-up completed in June 2004. | |
SEISMIC (Phase II Clinical Trial) | 40, including 14 controls. | Twelve sites in the Netherlands, Germany, Belgium, Spain, Poland, and the United Kingdom. | Phase II European study to assess the safety and efficacy of MyoCell® therapy delivered via MyoCath® catheter. | Trail commenced in November 2005; treatment of all patients completed in July 2007; final results presented in April 2008. |